Novo Nordisk's Triumph Over Obesity Paves the Way for Heart Disease Breakthrough

Novo Nordisk, known for its diabetes and obesity drugs, is expanding into the cardiovascular space with the goal of becoming an established cardiovascular company. The company's recent Select trial demonstrated that its drug Wegovy significantly reduces the risk of heart complications. Novo Nordisk is also developing treatments for heart disease and acquiring a medication for high blood pressure.